Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease

NCT: NCT02246374 · COMPLETED

NCT IDNCT02246374
StatusCOMPLETED
Start Date2014-09
Completion2021-05-18

Brief Summary

This is primarily a safety protocol to evaluate the safety of subthalamotomy using Transcranial ExAblate for treatment of Parkinson's Disease (PD) motor features.

Frequently Asked Questions

What is ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease?

ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease is a clinical trial registered under NCT02246374. Current status: COMPLETED.

What is the status of NCT02246374?

The current status of NCT02246374 (ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease) is: COMPLETED.

When did ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease start?

ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease started on 2014-09.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑